KR102442231B1 - 종양 치료를 위한 키누레닌 고갈 효소의 투여 - Google Patents

종양 치료를 위한 키누레닌 고갈 효소의 투여 Download PDF

Info

Publication number
KR102442231B1
KR102442231B1 KR1020217019661A KR20217019661A KR102442231B1 KR 102442231 B1 KR102442231 B1 KR 102442231B1 KR 1020217019661 A KR1020217019661 A KR 1020217019661A KR 20217019661 A KR20217019661 A KR 20217019661A KR 102442231 B1 KR102442231 B1 KR 102442231B1
Authority
KR
South Korea
Prior art keywords
leu
ala
gly
glu
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217019661A
Other languages
English (en)
Korean (ko)
Other versions
KR20210082264A (ko
Inventor
조지 조지우
에버렛 스톤
Original Assignee
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 filed Critical 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템
Publication of KR20210082264A publication Critical patent/KR20210082264A/ko
Application granted granted Critical
Publication of KR102442231B1 publication Critical patent/KR102442231B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y307/00—Hydrolases acting on carbon-carbon bonds (3.7)
    • C12Y307/01—Hydrolases acting on carbon-carbon bonds (3.7) in ketonic substances (3.7.1)
    • C12Y307/01003—Kynureninase (3.7.1.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020217019661A 2013-08-30 2014-08-29 종양 치료를 위한 키누레닌 고갈 효소의 투여 Active KR102442231B1 (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201361872132P 2013-08-30 2013-08-30
US61/872,132 2013-08-30
US201461986366P 2014-04-30 2014-04-30
US61/986,366 2014-04-30
PCT/US2014/053437 WO2015031771A2 (en) 2013-08-30 2014-08-29 Administration of kynurenine depleting enzymes for tumor therapy
KR1020167008486A KR102271498B1 (ko) 2013-08-30 2014-08-29 종양 치료를 위한 키누레닌 고갈 효소의 투여

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020167008486A Division KR102271498B1 (ko) 2013-08-30 2014-08-29 종양 치료를 위한 키누레닌 고갈 효소의 투여

Publications (2)

Publication Number Publication Date
KR20210082264A KR20210082264A (ko) 2021-07-02
KR102442231B1 true KR102442231B1 (ko) 2022-09-13

Family

ID=52583559

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020217019661A Active KR102442231B1 (ko) 2013-08-30 2014-08-29 종양 치료를 위한 키누레닌 고갈 효소의 투여
KR1020167008486A Active KR102271498B1 (ko) 2013-08-30 2014-08-29 종양 치료를 위한 키누레닌 고갈 효소의 투여

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020167008486A Active KR102271498B1 (ko) 2013-08-30 2014-08-29 종양 치료를 위한 키누레닌 고갈 효소의 투여

Country Status (12)

Country Link
US (5) US9808486B2 (cg-RX-API-DMAC7.html)
EP (2) EP3038636B1 (cg-RX-API-DMAC7.html)
JP (4) JP6307163B2 (cg-RX-API-DMAC7.html)
KR (2) KR102442231B1 (cg-RX-API-DMAC7.html)
CN (2) CN105722522B (cg-RX-API-DMAC7.html)
AU (1) AU2014312119B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016004095A2 (cg-RX-API-DMAC7.html)
CA (2) CA3173052A1 (cg-RX-API-DMAC7.html)
ES (1) ES2707711T3 (cg-RX-API-DMAC7.html)
IL (2) IL244312B (cg-RX-API-DMAC7.html)
WO (1) WO2015031771A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201601443B (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2934532B1 (en) 2012-12-20 2019-10-23 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
CA3173052A1 (en) 2013-08-30 2015-03-05 Board Of Regents, The University Of Texas System Administration of kynurenine depleting enzymes for tumor therapy
IL250833B (en) 2014-08-29 2022-09-01 Univ Texas Administration of kynurenine depleting enzymes for tumor therapy
AU2015332533B2 (en) 2014-10-14 2018-08-30 Halozyme, Inc. Compositions of adenosine deaminase-2 (ADA2), variants thereof and methods of using same
WO2016149665A1 (en) * 2015-03-18 2016-09-22 Baylor College Of Medicine Her2/erbb2 chimeric antigen receptor
WO2017123675A1 (en) 2016-01-11 2017-07-20 Synlogic, Inc. Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
EP3423483B1 (en) * 2016-03-02 2025-09-24 Board Of Regents Of the University Of Texas System Human kynureninase enzyme variants having improved pharmacological properties
CA3019835A1 (en) 2016-04-08 2017-10-12 Purdue Research Foundation Methods and compositions for car t cell therapy
EP3525803B1 (en) 2016-10-13 2022-12-07 Juno Therapeutics, Inc. Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators
AU2018219226B2 (en) 2017-02-07 2024-12-19 Seattle Children's Hospital (dba Seattle Children's Research Institute) Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
CN110582288B (zh) 2017-02-28 2024-09-20 恩多塞特公司 用于car t细胞疗法的组合物和方法
AU2018301668A1 (en) * 2017-07-12 2019-12-19 Synlogic Operating Company, Inc. Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
WO2019089740A1 (en) * 2017-11-03 2019-05-09 Dana-Farber Cancer Institute, Inc. Biomarkers of clinical response and benefit to immune checkpoint inhibitor therapy
WO2019144095A1 (en) 2018-01-22 2019-07-25 Seattle Children's Hospital (dba Seattle Children's Research Institute) Methods of use for car t cells
AU2019218729B2 (en) 2018-02-06 2025-12-04 Seattle Children's Hospital (dba Seattle Children's Research Institute) Fluorescein-specific CARs exhibiting optimal T cell function against FL-PLE labelled tumors
JP7568224B2 (ja) 2018-02-23 2024-10-16 エンドサイト・インコーポレイテッド Ｃａｒ ｔ細胞療法のための配列決定法
CA3096549A1 (en) 2018-04-16 2019-10-24 Board Of Regents, The University Of Texas System Human kynureninase enzymes and uses thereof
CN110412179A (zh) * 2018-04-26 2019-11-05 缪荣明 一种液相色谱检测颗粒酶a的方法
EP3893923A2 (en) * 2018-12-14 2021-10-20 Autolus Limited Cell
CN114828863A (zh) * 2019-10-17 2022-07-29 医肯纳肿瘤学公司 聚乙二醇化犬尿氨酸酶以及其用于治疗癌症的用途
IL295063A (en) 2020-02-04 2022-09-01 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Chimeric antigen receptors (car) against dinitrophenol
WO2023229024A1 (ja) * 2022-05-27 2023-11-30 富士フイルム株式会社 血液腫瘍の診断を補助する方法、血液腫瘍の診断を行うためのデータを得る方法、及びこれらの方法のためのキット
WO2024085280A1 (ko) * 2022-10-20 2024-04-25 서울대학교 산학협력단 신규한 키뉴레니나제 및 이의 용도

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008237022A (ja) * 2005-06-30 2008-10-09 Osaka Prefecture 非小細胞肺がんの予防・治療剤および診断薬
WO2012099441A2 (ko) 2011-01-21 2012-07-26 인제대학교산학협력단 트립토판 대사효소 유전자를 발현하는 줄기세포를 함유하는 면역 반응 억제용 조성물

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824311A (en) 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
US4870287A (en) 1988-03-03 1989-09-26 Loma Linda University Medical Center Multi-station proton beam therapy system
US5329028A (en) 1992-08-05 1994-07-12 Genentech, Inc. Carbohydrate-directed cross-linking reagents
US5846945A (en) 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
US5801005A (en) 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
GB9506466D0 (en) 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
US5760395A (en) 1996-04-18 1998-06-02 Universities Research Assoc., Inc. Method and apparatus for laser-controlled proton beam radiology
US5739169A (en) 1996-05-31 1998-04-14 Procept, Incorporated Aromatic compounds for inhibiting immune response
US6812339B1 (en) * 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
US20030194721A1 (en) 2001-09-19 2003-10-16 Incyte Genomics, Inc. Genes expressed in treated foam cells
US20030215840A1 (en) 2002-02-01 2003-11-20 Millennium Pharmaceuticals, Inc. Methods and compositions for treating cardiovascular disease using 1682, 6169, 6193, 7771, 14395, 29002, 33216, 43726, 69292, 26156, 32427, 2402, 7747, 1720, 9151, 60491, 1371, 7077, 33207, 1419, 18036, 16105, 38650, 14245, 58848, 1870, 25856, 32394, 3484, 345, 9252, 9135, 10532, 18610, 8165, 2448, 2445, 64624, 84237, 8912, 2868, 283, 2554, 9464, 17799, 26686, 43848, 32135, 12208, 2914, 51130, 19489, 21833, 2917, 59590, 15992, 2094, 2252, 3474, 9792, 15400, 1452 or 6585 molecules
CN1330774C (zh) * 2002-03-01 2007-08-08 国家人类基因组南方研究中心 犬尿氨酸水解酶多态性及其用途
WO2004094409A1 (en) * 2003-03-27 2004-11-04 Lankenau Institute For Medical Research Novel ido inhibitors and methods of use
US20070207158A1 (en) 2003-06-17 2007-09-06 Harrison Roger G Conjugate for the specific targeting of anticancer agents to tumor cells or tumor vasculature and production thereof
JP4733635B2 (ja) 2003-07-31 2011-07-27 イミューノメディクス、インコーポレイテッド 抗ｃｄ１９抗体
CA2663057C (en) 2006-09-19 2015-12-08 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
GB0625310D0 (en) * 2006-12-19 2007-01-24 Bioalvo Yeast platform construction and screening methods
JP5934099B2 (ja) 2009-10-01 2016-06-15 アメリカ合衆国 抗血管内皮増殖因子受容体−２キメラ抗原受容体及び癌の治療のためのその使用
EP3115373B1 (en) 2010-09-08 2019-08-28 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Chimeric antigen receptors with an optimized hinge region
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
KR20120085209A (ko) * 2011-01-21 2012-07-31 인제대학교 산학협력단 트립토판 대사효소 유전자를 발현하는 줄기세포를 함유하는 면역 반응 억제용 조성물
HK1201471A1 (en) * 2011-09-07 2015-09-04 Deutsches Krebsforschungszentrum Means and methods for treating and/or preventing natural ahr ligand-dependent cancer
JP6267644B2 (ja) 2011-10-20 2018-01-24 アメリカ合衆国 抗ｃｄ２２キメラ抗原受容体
CA3173052A1 (en) * 2013-08-30 2015-03-05 Board Of Regents, The University Of Texas System Administration of kynurenine depleting enzymes for tumor therapy
IL250833B (en) 2014-08-29 2022-09-01 Univ Texas Administration of kynurenine depleting enzymes for tumor therapy
EP3423483B1 (en) 2016-03-02 2025-09-24 Board Of Regents Of the University Of Texas System Human kynureninase enzyme variants having improved pharmacological properties
JP6912171B2 (ja) * 2016-09-15 2021-07-28 株式会社トプコン 眼科検査装置
CA3096549A1 (en) 2018-04-16 2019-10-24 Board Of Regents, The University Of Texas System Human kynureninase enzymes and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008237022A (ja) * 2005-06-30 2008-10-09 Osaka Prefecture 非小細胞肺がんの予防・治療剤および診断薬
WO2012099441A2 (ko) 2011-01-21 2012-07-26 인제대학교산학협력단 트립토판 대사효소 유전자를 발현하는 줄기세포를 함유하는 면역 반응 억제용 조성물

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J Med Chem. 2009, Vol.52, No.2, pp.389-396

Also Published As

Publication number Publication date
EP3038636B1 (en) 2018-11-07
US20240091258A1 (en) 2024-03-21
KR102271498B1 (ko) 2021-07-05
ES2707711T3 (es) 2019-04-04
US20200054674A1 (en) 2020-02-20
CA2922670C (en) 2022-11-29
EP3038636A2 (en) 2016-07-06
CA2922670A1 (en) 2015-03-05
NZ717492A (en) 2021-10-29
KR20160048971A (ko) 2016-05-04
US9808486B2 (en) 2017-11-07
KR20210082264A (ko) 2021-07-02
US12680089B2 (en) 2026-07-14
JP7029316B2 (ja) 2022-03-03
WO2015031771A2 (en) 2015-03-05
CA3173052A1 (en) 2015-03-05
JP2016533753A (ja) 2016-11-04
CN105722522A (zh) 2016-06-29
EP3492094A1 (en) 2019-06-05
JP6307163B2 (ja) 2018-04-04
JP2022159570A (ja) 2022-10-17
US10772913B2 (en) 2020-09-15
AU2014312119A1 (en) 2016-03-17
AU2014312119B2 (en) 2019-09-19
BR112016004095A2 (pt) 2017-10-17
ZA201601443B (en) 2019-08-28
EP3038636A4 (en) 2017-04-26
IL244312A0 (en) 2016-04-21
IL244312B (en) 2019-03-31
CN113957061A (zh) 2022-01-21
JP2018127463A (ja) 2018-08-16
WO2015031771A3 (en) 2015-05-14
US20150064154A1 (en) 2015-03-05
CN105722522B (zh) 2021-10-19
US11534463B2 (en) 2022-12-27
US20170056449A1 (en) 2017-03-02
US20210213059A1 (en) 2021-07-15
IL264901B (en) 2019-08-29
JP2020111611A (ja) 2020-07-27

Similar Documents

Publication Publication Date Title
KR102271498B1 (ko) 종양 치료를 위한 키누레닌 고갈 효소의 투여
US20220275099A1 (en) Administration of kynurenine depleting enzymes for tumor therapy
KR102269209B1 (ko) 항신생물제로서 조작된 영장류 시스틴/시스테인 분해 효소
KR102862473B1 (ko) 인간 키누레니나제 효소 및 이의 사용법
HK40067079A (en) Administration of kynurenine depleting enzymes for tumor therapy
HK1226335A1 (en) Administration of kynurenine depleting enzymes for tumor therapy
HK1226335B (en) Administration of kynurenine depleting enzymes for tumor therapy
NZ717492B2 (en) Administration of kynurenine depleting enzymes for tumor therapy

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20210624

Application number text: 1020167008486

Filing date: 20160330

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210720

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210811

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20220623

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20220906

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20220907

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20250701

Start annual number: 4

End annual number: 4